Genital Herpesvirus homonis infection in mice. II. Treatment with phosphonoacetic acid, adenine arabinoside, and adenine arabinoside 5'-monophosphate.
Genital infection of mice with Herpesvirus hominis type 2 provides an experimental model for screening potential antiviral chemotherapeutic agents before clinical trials in humans. Intravaginal treatment with phosphonoacetic acid (at a dose of 500 mg/kg in saline or as a 5% cream) initiated 3 hr after inoculation with H. hominis type 2 completely inhibited viral replication in the genital tract and prevented subsequent mortality. Although therapy initiated 24-72 hr after infection significantly reduced titers of virus in vaginal secretions from three- to 100-fold, most mice eventually died of encephalitis. Topical treatment with either adenine arabinoside or adenine arabinoside 5'-monophosphate at a dose of 500 mg/kg in saline or as a 10% cream failed to alter viral replication in the genital tract or to protect the mice from death due to encephalitis. Treatment by the intraperitoneal route with any of these three agents had no effect on local viral replication or final mortality.
D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy*; D051379:Mice; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D018139:Simplexvirus / Q000302:isolation & purification; D014621:Vagina / Q000382:microbiology; D014623:Vaginal Diseases / Q000276:immunology; D014740:Vidarabine / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D009943:Organophosphorus Compounds; D000249:Adenosine Monophosphate; D014740:Vidarabine